Back to Search
Start Over
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
- Source :
- Cell Reports; May2024, Vol. 43 Issue 5, pN.PAG-N.PAG, 1p
- Publication Year :
- 2024
-
Abstract
- Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously demonstrated that the PI3K pathway regulates ER activity through phosphorylation of the chromatin modifier KMT2D. Here, we discovered a methylation site on KMT2D, at K1330 directly adjacent to S1331, catalyzed by the lysine methyltransferase SMYD2. SMYD2 loss attenuates alpelisib-induced KMT2D chromatin binding and alpelisib-mediated changes in gene expression, including ER-dependent transcription. Knockdown or pharmacological inhibition of SMYD2 sensitizes breast cancer cells, patient-derived organoids, and tumors to PI3K/AKT inhibition and endocrine therapy in part through KMT2D K1330 methylation. Together, our findings uncover a regulatory crosstalk between post-translational modifications that fine-tunes KMT2D function at the chromatin. This provides a rationale for the use of SMYD2 inhibitors in combination with PI3Kα/AKT inhibitors in the treatment of ER+/ PIK3CA mutant breast cancer. [Display omitted] • KMT2D is methylated at K1330 by SMYD2 • There is crosstalk between phosphorylation of KMT2D at S1331 and methylation at K1330 • Loss of SMYD2 abrogates PI3Ki-induced KMT2D chromatin binding and ER-dependent transcription • Inhibition of KMT2D methylation sensitizes cells and tumors to PI3K/AKT inhibition Blawski et al. show that KMT2D is methylated by the lysine methyltransferase SMYD2 at K1330. SMYD2 loss attenuates PI3K inhibitor-induced KMT2D chromatin binding at estrogen-receptor (ER) loci and ER-dependent transcription. SMYD2 inhibition sensitizes cells, patient-derived organoids, and tumors to PI3K/AKT inhibition and endocrine therapy through KMT2D K1330 methylation. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 26391856
- Volume :
- 43
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Cell Reports
- Publication Type :
- Academic Journal
- Accession number :
- 177421025
- Full Text :
- https://doi.org/10.1016/j.celrep.2024.114174